The UK is a world leader in life science research. Yet many breakthroughs are lost in translation from preclinical animal models to humans. There is now a tremendous opportunity to bridge the translational gap with human relevant technologies.
It is time to focus on the human.

The Alliance for Human Relevant Science is an inclusive collaboration of like-minded companies, organisations and individuals. Working together, we will accelerate innovation and create positive change.


  • Support better science for better health
  • Save lives – human and animal – through improved safety and efficacy testing of medicines and other chemicals
  • Save money through more relevant research


Wednesday, January 13th, 2021

Next APPG meeting date confirmed.

Our second APPG meeting will be held (virtually) on Tuesday 9th February at 4pm UK time, where we will start the process of examining whether the current regulatory framework is designed to promote the implementation and adoption of human relevant technologies in the  UK.

Future meetings will focus on defining changes required in funding (May 2021) and regulations (Sept 2021) in order for these methods to be more widely adopted. A report of our findings will be available in Nov 2021. Call back here after the 9th February 2021 to hear what was discussed at the second meeting!

Click here for more info.

Monday, January 11th, 2021

CN Bio’s PhysioMimix™ technology receives FDA recognition

Alliance member CN Bio announces how a joint publication with the FDA demonstrates the advantages of their PhysioMimix™ in drug safety and metabolism applications, over standard techniques. This represents the first co-published, peer-reviewed article between a microphysiological system provider and a regulator:

Tuesday, October 6th, 2020

PRESS RELEASE New Parliamentary group calls for human relevant science moonshot

Tuesday 6 October, London: A new All-Party Parliamentary Group today held its first AGM with the aim of accelerating the development and uptake of human relevant life sciences in the UK.

The APPG on Human Relevant Science held its first meeting remotely on Tuesday 6 October, where the group outlined its priorities.

The APPG will be a discussion forum for politicians, the human relevant life sciences sector, third sector groups, scientists and stakeholders to promote new approach methodologies that provide unique insights into human biology, transform our ability to understand human disease and can develop effective new medicines more quickly and without the use of animals.

Its programme will cover the themes of strategic funding to incentivise the development and use of human relevant methods and technologies, and incorporation of human relevant methods into regulatory guidelines on medicines development.

The APPG’s statement of purpose is to bring together MPs and Peers of all parties to accelerate the development and uptake of human relevant life sciences in the UK.

Replacing poorly performing animal tests with innovative human relevant new approach methodologies will directly benefit the UK science base and enhance the efficiency and profitability of industries that make vital contributions to the UK economy.

Speaking at the launch, the APPG’s Chair, Labour MP Grahame Morris, said, “I am delighted to Chair the new All-Party Parliamentary Group on Human Relevant Science. The COVID-19 pandemic has demonstrated that the current approach to developing new treatments is simply not fast enough to meet humanity’s needs. We urgently need a moonshot to transition to new approach methodologies which promise to deliver safer and more effective medicines, more quickly and at less cost.”

APPG Vice Chair Conservative MP Sir David Amess said, “I am thrilled to be Vice Chair of the new All-Party Parliamentary Group on Human Relevant Science. With the cancellation of the Autumn Budget, the Government now has more time to think about what it can do to provide much-needed financial support to boost growth in the human relevant life sciences sector and enable the UK to remain an innovative science superpower.

“As the country seeks a COVID-19 vaccine, this is the perfect time for parliamentarians to take seriously the growing evidence in favour of the pioneering human relevant medical research techniques that are replacing the outdated use of animals.”

The Alliance for Human Relevant Science acts as the group’s secretariat.


For more information please contact the Cruelty Free International media office;

email:  or telephone: +44 (0) 7590055 206.


About the Alliance for Human Relevant Science

The Alliance for Human Relevant Science is an inclusive collaboration of like-minded companies, organisations and individuals, working together to show how significant advances in science and technology can deliver new methods based on human biology, with the potential to improve the safety of medicines and other chemicals.


Tuesday, July 14th, 2020


An open letter to:

International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
The International Coalition of Medicines Regulatory Authorities
European Medicines Agency
European Directorate for the Quality of Medicines and Healthcare
European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM)
Home Office
Department of Health and Social Care
Department for Business, Energy & Industrial Strategy
Medicines & Healthcare products Regulatory Agency
National Institute for Health and Care Excellence (NICE)

We are calling for a change of mindset and a clear timetable for regulatory change to enable accelerated development of medicines which are likely to be safer, more effective and cheaper, without the use of animals. Investment in human relevant science offers a golden opportunity to revitalise medical research, save money, create wealth and improve public health.

We find ourselves in a time of global health emergency, one that will challenge our healthcare, social fabric and economy for years to come. Hard choices today have been borne out of great and immediate need. Yet there are patterns emerging in the scientific response that will have far reaching consequences for how we progress medical science in the future.